CO2020005981A2 - Anticuerpos anti-tau y uso de los mismos - Google Patents

Anticuerpos anti-tau y uso de los mismos

Info

Publication number
CO2020005981A2
CO2020005981A2 CONC2020/0005981A CO2020005981A CO2020005981A2 CO 2020005981 A2 CO2020005981 A2 CO 2020005981A2 CO 2020005981 A CO2020005981 A CO 2020005981A CO 2020005981 A2 CO2020005981 A2 CO 2020005981A2
Authority
CO
Colombia
Prior art keywords
tau antibodies
antibodies
tau
methods
same
Prior art date
Application number
CONC2020/0005981A
Other languages
English (en)
Inventor
Jared Spidel
Shigeru Akasofu
Malcolm Ian Roberts
James Martin Staddon
Silva Hettihewage Alfred Rohan De
Hirofumi Aoyagi
Yutaka Hashizume
Kishan Agarwala
Original Assignee
Ucl Business Ltd
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Ltd, Eisai R&D Man Co Ltd filed Critical Ucl Business Ltd
Publication of CO2020005981A2 publication Critical patent/CO2020005981A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporciona en la presente anticuerpos que enlazan específicamente Tau y métodos para usar los mismos.
CONC2020/0005981A 2017-10-16 2020-05-15 Anticuerpos anti-tau y uso de los mismos CO2020005981A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762572910P 2017-10-16 2017-10-16
US201762577011P 2017-10-25 2017-10-25
US201862697034P 2018-07-12 2018-07-12
PCT/IB2018/058024 WO2019077500A1 (en) 2017-10-16 2018-10-16 ANTI-WATER ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number Publication Date
CO2020005981A2 true CO2020005981A2 (es) 2020-07-31

Family

ID=64100697

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0005981A CO2020005981A2 (es) 2017-10-16 2020-05-15 Anticuerpos anti-tau y uso de los mismos

Country Status (21)

Country Link
US (4) US10829547B2 (es)
EP (1) EP3697814A1 (es)
JP (2) JP6851549B2 (es)
KR (2) KR20200058480A (es)
CN (1) CN111630064B (es)
AU (1) AU2018352308B2 (es)
BR (1) BR112020007536A2 (es)
CA (1) CA3077247A1 (es)
CL (3) CL2020001003A1 (es)
CO (1) CO2020005981A2 (es)
IL (2) IL273832B (es)
JO (1) JOP20200074A1 (es)
MA (1) MA50397A (es)
MX (1) MX2020003857A (es)
PE (2) PE20210115A1 (es)
PH (2) PH12020551216A1 (es)
SG (1) SG11202003392VA (es)
TW (3) TWI853617B (es)
UA (1) UA129617C2 (es)
WO (1) WO2019077500A1 (es)
ZA (1) ZA202001548B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24446B1 (es) 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
CN109219615B (zh) 2016-05-02 2022-12-09 普罗塞纳生物科学有限公司 识别tau的抗体
EP3583123A1 (en) 2017-02-17 2019-12-25 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
EP3619233A4 (en) 2017-05-02 2021-03-03 Prothena Biosciences Limited ANTIBODIES RECOGNIZING TAU PROTEIN
JP6851549B2 (ja) * 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
WO2020180819A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
US12060434B2 (en) * 2020-02-25 2024-08-13 Gensun Biopharma Inc. Trispecific T cell engagers
US20220064271A1 (en) * 2020-09-01 2022-03-03 Washington University Methods for treating tauopathies
EP4222160A1 (en) * 2020-10-02 2023-08-09 Eli Lilly and Company Methods for reducing host cell protein content in antibody purification processes and antibody compositions having reduced host cell protein content
KR20240033017A (ko) 2021-07-09 2024-03-12 에자이 알앤드디 매니지먼트 가부시키가이샤 알츠하이머병 치료를 위한 바이오마커
CA3237660A1 (en) 2021-11-03 2023-05-11 Eisai R&D Management Co., Ltd. Anti-tau antibody compositions, dosage forms, and methods
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023111618A1 (en) 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
JP2024547001A (ja) 2021-12-17 2024-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法
TW202339794A (zh) 2022-02-02 2023-10-16 日商衛材R&D企管股份有限公司 使用p—tau181水平之治療方法
WO2024059739A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. Tau binding compounds
TW202430554A (zh) 2022-11-28 2024-08-01 日商衛材R&D企管股份有限公司 使用tau PET水平之治療方法
WO2024254542A1 (en) 2023-06-09 2024-12-12 Eisai R&D Management Co., Ltd. Methods of treatment using an anti-abeta protofibril antibody
WO2025019457A1 (en) 2023-07-15 2025-01-23 Eisai R&D Management Co., Ltd. Antimicrobial peptides
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025137359A1 (en) 2023-12-20 2025-06-26 Eisai R&D Management Co., Ltd. Assay methods to identify a disease

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US7982017B2 (en) 2007-12-18 2011-07-19 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EA032675B1 (ru) 2009-06-10 2019-07-31 Нью-Йорк Юниверсити Способ и композиции для лечения болезни альцгеймера и других таупатий
US9304138B2 (en) 2010-10-07 2016-04-05 Katholieke Universiteit Leuven Pharmaceutical composition
HRP20181320T8 (hr) 2010-10-11 2018-12-14 Biogen International Neuroscience Gmbh Ljudska anti-tau protutijela
AU2012229222A1 (en) 2011-03-11 2013-09-12 Ramot At Tel-Aviv University Ltd. Method for treating neurodegenerative tauopathy
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
CA2848346A1 (en) 2011-09-19 2013-03-28 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
EP3578567A1 (en) 2011-12-20 2019-12-11 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
EP2834270B1 (en) * 2012-04-05 2019-10-30 AC Immune S.A. Humanized tau antibody
WO2013177104A2 (en) 2012-05-21 2013-11-28 Felder Mitchell S Treatment for tauopathies
WO2013180238A1 (ja) 2012-05-31 2013-12-05 公立大学法人大阪市立大学 認知症治療剤又は予防剤
NZ703423A (en) * 2012-07-03 2018-02-23 Univ Washington Antibodies to tau
EP2885010B1 (en) 2012-08-16 2020-01-01 Ipierian, Inc. Methods of treating a tauopathy
US9650436B2 (en) 2012-10-12 2017-05-16 Arizona Board Of Regents On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
WO2014089104A1 (en) 2012-12-03 2014-06-12 Washington University Method for detection of aggregates in biological samples
DK2935326T3 (da) 2012-12-21 2020-09-14 Biogen Ma Inc Humane anti-tau-antistoffer
WO2014096321A1 (en) 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies
CU24446B1 (es) 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
WO2014150877A2 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
CN105339002B (zh) 2013-06-10 2019-06-28 伊皮埃里安股份有限公司 治疗tau病变的方法
GB201312226D0 (en) 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
EP3083680B1 (en) 2013-12-20 2020-01-15 F. Hoffmann-La Roche AG Humanized anti-tau(ps422) antibodies and methods of use
JP6341274B2 (ja) 2014-05-07 2018-06-13 株式会社村田製作所 弾性表面波装置
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
CN107074965B (zh) 2014-06-26 2021-08-03 扬森疫苗与预防公司 特异性结合微管相关蛋白tau的抗体和抗原结合片段
TW202136296A (zh) * 2014-06-27 2021-10-01 美商C2N醫療診斷有限責任公司 人類化抗-tau抗體
DE102014013571A1 (de) 2014-09-18 2016-03-24 Aj Roboscreen Gmbh Monoklonaler Antikörper gegen humanes TAU-Protein
PL3221349T3 (pl) 2014-11-19 2021-05-17 Axon Neuroscience Se Humanizowane przeciwciała tau w chorobie Alzheimera
WO2016086033A2 (en) 2014-11-25 2016-06-02 Abbott Diabetes Care Inc. Analyte monitoring systems and related test and monitoring methods
WO2016112078A2 (en) 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
WO2016137950A1 (en) 2015-02-24 2016-09-01 Rpeptide, Llc Anti-tau antibodies
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對tau之抗體及其用途
IL300670B2 (en) 2015-06-05 2025-02-01 Genentech Inc Anti-tau antibodies and methods of use
CA2991451A1 (en) 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies
AU2016289753C1 (en) 2015-07-06 2021-08-05 UCB Biopharma SRL Tau-binding antibodies
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US9704904B2 (en) * 2015-08-27 2017-07-11 Taiwan Semiconductor Manufacturing Company, Ltd. Deep trench isolation structures and methods of forming same
WO2017062496A2 (en) 2015-10-05 2017-04-13 University Of Virginia Patent Foundation Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
AU2016334051B2 (en) * 2015-10-06 2023-10-26 Alector Llc Anti-TREM2 antibodies and methods of use thereof
CN109219615B (zh) 2016-05-02 2022-12-09 普罗塞纳生物科学有限公司 识别tau的抗体
MX2018013386A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
CN116041504A (zh) 2016-07-12 2023-05-02 H.隆德贝克有限公司 特异性针对过度磷酸化τ蛋白的抗体及其使用方法
EP3583123A1 (en) 2017-02-17 2019-12-25 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
JOP20180014A1 (ar) 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
EP3619233A4 (en) * 2017-05-02 2021-03-03 Prothena Biosciences Limited ANTIBODIES RECOGNIZING TAU PROTEIN
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用

Also Published As

Publication number Publication date
JP6851549B2 (ja) 2021-03-31
MX2020003857A (es) 2021-01-08
US11578120B2 (en) 2023-02-14
CN111630064A (zh) 2020-09-04
US20190112365A1 (en) 2019-04-18
AU2018352308B2 (en) 2025-06-05
US20240034777A1 (en) 2024-02-01
JP7223794B2 (ja) 2023-02-16
IL273832B (en) 2022-06-01
PH12020550243A1 (en) 2021-02-15
JP2020536534A (ja) 2020-12-17
RU2020115817A3 (es) 2022-04-08
PE20212088A1 (es) 2021-11-04
IL273832A (en) 2020-05-31
RU2020115817A (ru) 2021-11-18
PH12020551216A1 (en) 2024-06-24
EP3697814A1 (en) 2020-08-26
TWI809562B (zh) 2023-07-21
TW202340244A (zh) 2023-10-16
US10829547B2 (en) 2020-11-10
UA129617C2 (uk) 2025-06-18
MA50397A (fr) 2020-08-26
CL2021000517A1 (es) 2021-09-24
PE20210115A1 (es) 2021-01-19
AU2018352308A1 (en) 2020-03-19
JOP20200074A1 (ar) 2020-04-30
KR102225178B1 (ko) 2021-03-10
US20210024622A1 (en) 2021-01-28
BR112020007536A2 (pt) 2020-09-29
ZA202001548B (en) 2021-10-27
US10358485B2 (en) 2019-07-23
KR20200051035A (ko) 2020-05-12
CA3077247A1 (en) 2019-04-25
US20190112364A1 (en) 2019-04-18
CL2021000516A1 (es) 2021-09-24
WO2019077500A1 (en) 2019-04-25
SG11202003392VA (en) 2020-05-28
JP2021097698A (ja) 2021-07-01
TWI750419B (zh) 2021-12-21
TW202207985A (zh) 2022-03-01
KR20200058480A (ko) 2020-05-27
TW201927817A (zh) 2019-07-16
IL290783A (en) 2022-04-01
CN111630064B (zh) 2023-06-27
TWI853617B (zh) 2024-08-21
CL2020001003A1 (es) 2020-10-02

Similar Documents

Publication Publication Date Title
CO2020005981A2 (es) Anticuerpos anti-tau y uso de los mismos
CL2019003114A1 (es) Anticuerpos anti–tau y métodos de uso (divisional solicitud 201703063)
MX2024011869A (es) Anticuerpos anti-tau y metodos de uso
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
CR20190271A (es) Anticuerpos antitau y métodos de uso
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CY1122653T1 (el) Αντισωματα αντι-τιgιτ, αντισωματα αντι-ρvrig και συνδυασμοι εξ αυτων
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
CL2020002540A1 (es) Anticuerpos anti-hla-g y utilización de los mismos
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
BR112019012342A2 (pt) anticorpos il-11
BR112019012343A2 (pt) anticorpos il-11ra
CL2017003240A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
CR20180605A (es) Anticuerpos anti-cd40 y sus usos
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
MX2019004690A (es) Constructos de anticuerpos.
CL2022000087A1 (es) Anticuerpo anti-tau y uso del mismo
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
MX2016016886A (es) Anticuerpos anti-axl.
MX2017015817A (es) Anticuerpos de union a tau.
CL2018001139A1 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos.
MX2018008302A (es) Anticuerpo antigrupo de diferenciacion 9 (anti-cd9) terapeutico.
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
CR20200404A (es) Anticuerpos anti-klk5 y métodos de uso